Profound Medical Corp.
- Jurisdiction
Canada - ISIN
CA74319B5027 (PRN.TO )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
3
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
3
/ 7
Profile
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland. Read full profile
Fundamentals
- Net revenue
€9.70M - Gross margin
68.6% - EBIT
-€36.44M - EBIT margin
-375.7% - Net income
-€35.07M - Net margin
-361.7%
Statement period: - (published )
Stock price
Dividends
No dividend payouts
Analyst ratings
No analyst ratings available
Insider Transactions
No insider transactions in the last 90 days. View older insider transactions
Earnings Calls
Earnings Calls
Latest earnings call: August 14, 2025 (Q2 2025)